Table 6 Mortality, ICU admission and related events after propensity score matching
Interventional cohort | Observational cohort | P-value | |||
|---|---|---|---|---|---|
N | Median (IQR) or n (%) | N | Median (95% CI) or n (%) | ||
Death within 30 days from heparin onset | 88 | 3 (3.4%) | 90 | 1 (1.1%) | 0.37 |
Cause of death at 30 days | 3 | 1 | |||
COVID-19 | 2 (66.7%) | 1 (100.0%) | |||
COVID-19 complications | 1 (33.3%) | 0 (0.0%) | |||
Death within 90 days from heparin onset | 89 | 3 (3.4%) | 90 | 1 (1.1%) | 0.37 |
Cause of death at 90 days | 3 | 1 | |||
COVID-19 | 2 (66.7%) | 1 (100.0%) | |||
COVID-19 complications | 1 (33.3%) | 0 (0.0%) | |||
Length of hospitalization [days] | 85 | 14 (9, 16) | 85 | 14 (10, 20) | 0.08 |
NIV | 90 | 14 (15.6%) | 90 | 10 (11.1%) | 0.51 |
CPAP | 90 | 11 (12.2%) | 90 | 11 (12.2%) | 1.00 |
High nasal O2 flow | 90 | 16 (17.8%) | 90 | 14 (15.6%) | 0.84 |
ICU admission | 90 | 12 (13.3%) | 90 | 8 (8.9%) | 0.48 |
Length of ICU stay [days] | 8 | 8 (5, 17) | 8 | 6 (5, 10) | 0.76 |
Death within 90 days or ICU admission | 89 | 13 (14.6%) | 90 | 9 (10.0%) | 0.37 |
Improvement of clinical status between visit 1 and visit 3 | 90 | 58 (64.4%) | 90 | 52 (57.8%) | 0.36 |